Despite the common practice of switching patients from one medicine to another—to improve efficacy, safety, or tolerability—guidance on how to do so is uncommon. During this time of global shortage of glucagon-like peptide-1 receptor agonist (GLP-1 RA) ± glucose-dependent insulinotropic polypeptide (GIP) RA therapies, this research letter offers a quick clinical reference of rough equivalency between GLP-1 ± GIP RA for A1c and body weight reduction in people with type 2 diabetes.

CONFLICT OF INTEREST STATEMENT

Leigh Perreault has received person fees for speaking and/or consulting from Novo Nordisk, Elli Lilly, Boehringer Ingelheim, Neurobo, Medscape, WebMD, and UpToDate. Bryan C. Bergman has no conflicts to declare.

REFERENCES

1Jung H, Tittel SR, Schloot NC, et al. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: a retrospective analysis of the Diabetes Prospective Follow-Up registry. Diabetes Obes Metab. 2023; 25(7): 1813-1822.
10.1111/dom.15038
CAS PubMed Web of Science® Google Scholar
2Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45(11): 2753-2786.
10.2337/dci22-0034
CAS PubMed Web of Science® Google Scholar
3Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017; 5(5): 341-354.
10.1016/S2213-8587(17)30092-X
CAS PubMed Web of Science® Google Scholar
4Frias JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021; 9(9): 563-574.
10.1016/S2213-8587(21)00174-1
CAS PubMed Web of Science® Google Scholar
5Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and safety of Dulaglutide 3.0 mg and 4.5 mg versus Dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021; 44(3): 765-773.
10.2337/dc20-1473
PubMed Web of Science® Google Scholar
6Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021; 385(6): 503-515.
10.1056/NEJMoa2107519
CAS PubMed Web of Science® Google Scholar
7Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009; 32(1): 84-90.
10.2337/dc08-1355
CAS PubMed Web of Science® Google Scholar
8Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019; 321(1): 69-79.
10.1001/jama.2018.18269
CAS PubMed Web of Science® Google Scholar
9Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012; 35(2): 252-258.
10.2337/dc11-1107
CAS PubMed Web of Science® Google Scholar
10Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015; 17(9): 849-858.
10.1111/dom.12479
CAS PubMed Web of Science® Google Scholar
11Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021; 12:2042018821997320.
10.1177/2042018821997320
Web of Science® Google Scholar

Citing Literature

Volume16, Issue6

June 2024

e13505

Out of stock: A brief clinical reference for rough equivalency of glucagon-like peptide-1 (GLP-1) ± glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes

Abstract

CONFLICT OF INTEREST STATEMENT

REFERENCES

Citing Literature

Figures

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Out of stock: A brief clinical reference for rough equivalency of glucagon-like peptide-1 (GLP-1) ± glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes

Abstract

CONFLICT OF INTEREST STATEMENT

REFERENCES

Citing Literature

Figures

References

Related

Information